Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 5/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | P4HB | P07237 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31023777 | 0.89 | USP2 (0.51) | USP2CYP2D6CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL31023729 | 0.88 | USP2 (0.47) | USP2CYP2D6CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL31023800 | 0.83 | CYP2D6 (0.42) | USP2CYP2D6CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL31023772 | 0.83 | P4HB (0.47) | CYP2D6P4HBSMAD3 | |
| SCHEMBL31023682 | 0.81 | USP2 (0.37) | USP2CYP2D6CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL31023937 | 0.79 | P4HB (0.44) | CYP2D6P4HBSMAD3ALDH1A1 | |
| SCHEMBL31023904 | 0.75 | GPR183 (0.49) | USP2CYP2D6CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL31023960 | 0.72 | CYP3A4 (0.44) | USP2CYP2D6CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL31023645 | 0.70 | SLC6A2 (0.38) | — | |
| SCHEMBL31023728 | 0.68 | HDAC3 (0.36) | USP2CYP2D6CYP3A4CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665718-A1 | SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF | Apogee Pharmaceuticals, Inc. (CA) | 2025-12-24 | — | — | EP | disclosed |
| US-12378231-B2 | Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof | APOGEE PHARMACEUTICALS, INC. (CA) | 2025-08-05 | — | — | US | disclosed |
| US-20240294514-A1 | SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF | APOGEE PHARMACEUTICALS, INC. (CA) | 2024-09-05 | — | — | US | disclosed |
| WO-2024168426-A1 | SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF | APOGEE PHARMACEUTICALS, INC. (CA) | 2024-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12378231-B2 | Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof | MGLL, PNLIP, LPL | USP2 1903/4885CYP2D6 727/4885CYP3A4 2196/4885 |
| US-20240294514-A1 | SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF | MGLL, PNLIP, LPL | USP2 1903/4885CYP2D6 727/4885CYP3A4 2196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.